Search - tctmd.com

Displaying 81 - 100 of 485

Sort: Relevancy | Date

Presentation TCT 2018

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

Presenter: David J. Cohen, Sunil V. Rao, Ajay J. Kirtane

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation TCT 2018

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Presenter: David J. Cohen, Sunil V. Rao, John A. Spertus

September 22, 2018

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

Presentation TCT 2018

Ultra-Thin Strut DES: A Meaningful Advance?

Presenter: Renu Virmani, Clemens von Birgelen, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Presenter: Renu Virmani, Clemens von Birgelen, David E. Kandzari

September 22, 2018

Presentation TCT 2018

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

Presenter: Renu Virmani, Clemens von Birgelen, Michael Joner

September 22, 2018

Presentation TCT 2018

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Ricardo A. Costa

September 21, 2018

Presentation TCT 2018

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

Presenter: Antonio L. Bartorelli, David G. Rizik, Michael Haude

September 21, 2018

Presentation TCT 2018

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Dean J. Kereiakes

September 21, 2018

Presentation TCT 2018

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Presenter: Antonio L. Bartorelli, David G. Rizik, Patrick W. Serruys

September 21, 2018

Presentation TCT 2018

What is the Future of Bioresorbable Scaffolds?

Presenter: Jeroen J. Bax, Stephan Windecker, Michael Haude

September 21, 2018

Presentation ESC 2018

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Presenter: Holger M. Nef

August 29, 2018

Presentation ACC 2018

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Presenter: Ajay J. Kirtane

March 11, 2018

Advertisement

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Increasing Emphasis on QOL Outcomes: From Patient Preference to Instrument Validation

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Ultra-Thin Strut DES: A Meaningful Advance?

Can Contemporary DES Be Improved by Altering the Drug, Polymer, Alloy or Construction?

Keynote: Why Do Contemporary DES Fail (Early and Late, Restenosis and Thrombosis)?

TCT-64: Two-Year Clinical and Imaging Outcomes of Thin Strut Sirolimus-Eluting Bioresorbable Vascular Scaffolds in De Novo Coronary Artery Lesions: The MeRes-1 Trial

TCT-63: Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries at 24-month follow-up - BIOSOLVE-II and BIOSOLVE-III

TCT-61: Clinical Outcomes Following Complete Bioresorption of the Absorb Everolimus-Eluting Bioresorbable Scaffold: Four-year Results from the ABSORB III Trial

TCT-62: Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

What is the Future of Bioresorbable Scaffolds?

Outcomes of 10.312 Patients Treated with Everolimus-eluting Bioresorbable Scaffolds During Daily Clinical Practice: Results from the European Absorb Consortium

Uptake and Utilization of Drug-Eluting Bioresorbable Vascular Scaffolds: A CathPCI Registry Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content